Integrating fine needle aspiration and single-cell RNA sequencing for studying metabolic dysfunction-associated steatotic liver disease - Takeaways - MDSpire

Combining Fine Needle Aspiration with Single-Cell RNA Sequencing to Investigate Metabolic Dysfunction-Related Steatotic Liver Disease

  • By

  • Matthew P. Salomon

  • Lucy Golden-Mason

  • Ivetta Vorobyova

  • Gary C. Kanel

  • Yufen Wang

  • Daphne Wong

  • Ana C. Maretti-Mira

  • July 20, 2026

Share

  • 1

    Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease and hepatocellular carcinoma.

  • 2

    The study proposes combining fine-needle aspiration (FNA) with single-cell RNA sequencing (scRNA-seq) for longitudinal immune profiling in MASLD.

  • 3

    This approach allows for high-precision sampling of immune cells during metabolic dysfunction-associated steatohepatitis (MASH) progression.

  • 4

    The study identified dynamic shifts in the hepatic immune landscape following dietary interventions in a mouse model.

  • 5

    The FNA-scRNA-seq framework supports reduced animal use in chronic liver disease research while providing valuable immunological insights.

Original Source(s)

Integrating fine needle aspiration and single-cell RNA sequencing for studying metabolic dysfunction-associated steatotic liver disease

  • by Matthew P. Salomon, Lucy Golden-Mason, Ivetta Vorobyova, Gary C. Kanel, Yufen Wang, Daphne Wong, Ana C. Maretti-Mira

  • July 20, 2026

Related Content

The longstanding issue of the benefit of ursodeoxycholic acid in primary sclerosing cholangitis: a long-term population-based study

Editorial: The MASLD spectrum: an emerging epidemic of cardiometabolic and extra-hepatic dimensions

High-resolution mapping of chromatin conformation in HBeAg-treated macrophage provides insights into pathogenesis of HBV-related liver diseases